Poxviridae Infections: Clinical Trials

58 trials for Poxviridae Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

43 completed, 4 active not recruiting, 4 terminated, 3 recruiting. 58 Phase 2, 12 Phase 1, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 258Completed 43, Active not recruiting 4, Terminated 4, Recruiting 3, Unknown 2, Not yet recruiting 1, Withdrawn 1
Phase 112Completed 10, Terminated 1, Unknown 1
Phase 34Completed 3, Unknown 1

Follow Poxviridae Infections: new trials by email Literature Review of Poxviridae Infections trials Research Report on Poxviridae Infections

Trials (filtered) newest first · largest first

All 58 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
BNT166a, Placebo - Mpox (Monkeypox), Smallpox
Phase 2RecruitingBioNTech SE3102026-02-202026-08-11
Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo
MVA-SIBP low dose, MVA-SIBP high dose, MVA-BN - Monkeypox (Mpox)
Phase 2Not yet recruitingShanghai Institute Of Biological Products1802025-12-312025-11-28
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Jynneos, MVA-BN (Quail) - Monkeypox (Mpox)
Phase 2Active not recruitingBavarian Nordic9702025-10-272026-04-08
An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC
Mpox vaccination with MVA-BN - Mpox (Monkeypox)
Phase 2Active not recruitingInstitute of Tropical Medicine, Belgium6002025-08-042026-11-18
Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
Recombinant human IL-21-expressing oncolytic vaccinia virus injection - Advanced Pancreatic Cancer
Phase 2RecruitingHangzhou Converd Co., Ltd.122025-05-292026-02-27
Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections
MVA-BN - Monkeypox (Mpox)
Phase 2Active not recruitingBavarian Nordic4602024-10-212025-11-24
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC - Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma
Phase 2RecruitingGenelux Corporation1422024-09-262026-06-04
A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines
BNT166a - Monkeypox
Phase 1 / Phase 2CompletedBioNTech SE962023-09-212026-09-15
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
mRNA-1769, Placebo - Smallpox, Mpox
Phase 1 / Phase 2CompletedModernaTX, Inc.3512023-08-152025-07-16
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
JYNNEOS - Monkeypox
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)4502023-03-222026-03-27
Tecovirimat for Treatment of Monkeypox Virus
Tecovirimat Oral Capsule, Placebo - Monkeypox
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)5972022-10-102025-10-09
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
JYNNEOS - Monkeypox
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)2292022-09-092026-04-16
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
Tecovirimat, Smallpox and Mpox Vaccine, Placebo - Smallpox
Phase 2Active not recruitingSIGA Technologies1002022-04-052026-09-14
Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years
VAC∆6 vaccine (10⁷ PFU), VAC∆6 vaccine (10⁶ PFU), Live Smallpox Vaccine - Smallpox, Monkeypox
Phase 2 / Phase 3CompletedFederal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"3342021-10-012023-05-06
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
BT-001, Pembrolizumab [KEYTRUDA®] - Metastatic Cancer, Soft Tissue Sarcoma
Phase 1 / Phase 2TerminatedTransgene312021-02-252025-11-21
FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues
Immunohistochemical staining with anti-FOS - Colorectal Cancer, Monkey Pox
Phase 2 / Phase 3Unknownxiaoliang Huang1202020-12-012023-01-26
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
mFOLFOX6, MVA-BN-CV301, FPV-CV301 - Metastatic Colorectal Cancer
Phase 2TerminatedPatrick Boland172018-06-262025-07-22
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
SB206 4%, SB206 8%, SB206 12% - Molluscum Contagiosum
Phase 2CompletedNovan, Inc.2562018-01-242023-05-06
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
VP-102 with applicator - Molluscum Contagiosum
Phase 2CompletedVerrica Pharmaceuticals Inc.332017-06-082021-08-11
A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum
VBP-245 Topical Gel, Vehicle - Molluscum Contagiosum
Phase 2CompletedVeloce BioPharma LLC1102017-02-272018-10-11

Showing 20 of 58. Sign in to see all of them.

Narrower conditions

Smallpox (31)  ·  Mpox, Monkeypox (12)  ·  Vaccinia (12)  ·  Molluscum Contagiosum (7)  ·  Neoplasms (4)  ·  Carcinoma (3)  ·  Colorectal Neoplasms (3)  ·  Carcinoma, Hepatocellular (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Cowpox (2)  ·  Liver Neoplasms (2)  ·  Melanoma (2)  ·  Neoplasms by Histologic Type (2)  ·  Ovarian Neoplasms (2)

Broader conditions

DNA Virus Infections (58)  ·  Infections (58)  ·  Virus Diseases (57)  ·  Animal Diseases (13)  ·  Primate Diseases (12)  ·  Rodent Diseases (12)  ·  Neoplasms by Site (11)  ·  Skin Diseases (10)  ·  Skin and Connective Tissue Diseases (10)  ·  Digestive System Diseases (8)  ·  Digestive System Neoplasms (8)  ·  Neoplasms (8)  ·  Skin Diseases, Infectious (7)  ·  Skin Diseases, Viral (6)

Interventions

smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic (20)  ·  Smallpox Vaccine (5)  ·  DryVax vaccine (3)  ·  tecovirimat (3)  ·  Cantharidin (2)  ·  Nivolumab (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  ACAM2000 (1)  ·  Aventis Pasteur smallpox vaccine (1)  ·  Bevacizumab (1)  ·  Cisplatin (1)  ·  Docetaxel (1)  ·  Irinotecan (1)  ·  Pemetrexed (1)  ·  Sorafenib (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (14)  ·  Bavarian Nordic (9)  ·  Jennerex Biotherapeutics (3)  ·  BioNTech SE (2)  ·  Emergent BioSolutions (2)  ·  Genelux Corporation (2)  ·  SIGA Technologies (2)  ·  Sanofi Pasteur, a Sanofi Company (2)  ·  Andrea McCart (1)  ·  Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" (1)  ·  Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina (1)  ·  Genelux GmbH (1)  ·  Hangzhou Converd Co., Ltd. (1)  ·  Institute of Tropical Medicine, Belgium (1)  ·  ModernaTX, Inc. (1)

Countries

United States (36)  ·  Democratic Republic of the Congo (4)  ·  France (4)  ·  Germany (4)  ·  Canada (3)  ·  South Korea (3)  ·  China (2)  ·  Puerto Rico (2)  ·  Switzerland (2)  ·  United Kingdom (2)  ·  Belgium (1)  ·  Hong Kong (1)  ·  Mexico (1)  ·  Russia (1)  ·  South Africa (1)

Top investigators

James Burke, MD (2)  ·  Richard N Greenberg, MD (2)  ·  Daniel Oertli, M.D. (1)  ·  David H Kirn, MD (1)  ·  Dennis Hruby, Ph.D. (1)  ·  Derek Jonker, MD (1)  ·  Edgar T Overton, MD (1)  ·  Erik Ross, MD (1)  ·  Frank von Sonnenburg, Prof (1)  ·  Gary Goldenberg, MD (1)  ·  Giulio C Spagnoli, M.D. (1)  ·  Helen MacKay, MD (1)  ·  Hypolite Muhindo Mavoko (1)

Results publications

PMID 36408618, PMID 11874634, PMID 14577912, PMID 19935776, PMID 19944151, PMID 20350190, PMID 20350191, PMID 20600480, PMID 21921208, PMID 22011376, PMID 23393196, PMID 23664987, PMID 25879867, PMID 26439129, PMID 27327616, PMID 28256358, PMID 29773661, PMID 31413923, PMID 32057574, PMID 33400412, PMID 33675226, PMID 37227734, PMID 38366591, PMID 40239067, PMID 41319397, PMID 42235570, PMID 42372625, PMID 42383154, PMID 42532635

NIH funding

U54AI057159 (1)